PharmaCyte Biotech Beheer

Beheer criteriumcontroles 3/4

De CEO PharmaCyte Biotech is Josh Silverman, benoemd in Oct2022, heeft een ambtstermijn van 2.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 787.92K, bestaande uit 46.3% salaris en 53.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.65% van de aandelen van het bedrijf, ter waarde $ 87.50K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6 jaar en 2.8 jaar.

Belangrijke informatie

Josh Silverman

Algemeen directeur

US$787.9k

Totale compensatie

Percentage CEO-salaris	46.3%
Dienstverband CEO	2.1yrs
Eigendom CEO	0.7%
Management gemiddelde ambtstermijn	6yrs
Gemiddelde ambtstermijn bestuur	2.8yrs

Recente managementupdates

Recent updates

PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business

Mar 22

PharmaCyte Biotech says CEO to step down, announces strategic review of business

Oct 07

PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors

Aug 15

Is This A Good Time To Invest In PharmaCyte?

Jan 07

PharmaCyte Biotech: Buy The 'Dump'

Aug 21

Analyse CEO-vergoeding

Hoe is Josh Silverman's beloning veranderd ten opzichte van PharmaCyte Biotech's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jul 31 2024	n/a	n/a	US$4m
Apr 30 2024	US$788k	US$365k	-US$17m
Jan 31 2024	n/a	n/a	-US$15m
Oct 31 2023	n/a	n/a	-US$10m
Jul 31 2023	n/a	n/a	-US$10m
Apr 30 2023	US$198k	US$188k	-US$4m

Compensatie versus markt: De totale vergoeding ($USD 787.92K ) Josh } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 650.80K ).

Compensatie versus inkomsten: De vergoeding van Josh is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Josh Silverman (54 yo)

2.1yrs

Tenure

US$787,923

Compensatie

Mr. Joshua N. Silverman, also known as Josh, is Independent Chairman of the Board of Petros Pharmaceuticals, Inc. Mr. Joshua N. Silverman, also known as Josh, serves as an Independent Director at Femasys I...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Joshua Silverman	Interim CEO	2.1yrs	US$787.92k	0.65% $ 87.5k
Carlos Trujillo	Chief Financial Officer	7.7yrs	US$586.56k	0.14% $ 18.2k
Jose Iglesias	Consulting Chief Medical Officer	4.3yrs	geen gegevens	geen gegevens
Hans-Peter Hammes	Member of Medical & Scientific Advisory Board and Consultant	9yrs	geen gegevens	geen gegevens

6.0yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van PMCB is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Joshua Silverman	Interim CEO	2.3yrs	US$787.92k	0.65% $ 87.5k
Hans-Peter Hammes	Member of Medical & Scientific Advisory Board and Consultant	9yrs	geen gegevens	geen gegevens
Robert Weinstein	Independent Director	2yrs	US$290.00k	0% $ 0
Brian Salmons	Member of Medical & Scientific Advisory Board	8.5yrs	geen gegevens	geen gegevens
Matthias Löhr	Chairman of Medical & Scientific Advisory Board	2.8yrs	US$16.76k	geen gegevens
Michael Abecassis	Independent Director	7.3yrs	US$296.00k	0.036% $ 4.9k
Wayne Walker	Independent Director	1.9yrs	US$265.00k	0% $ 0
Mark Rabe	Member of Medical & Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jonathan Schechter	Independent Director	2.3yrs	US$290.00k	0.65% $ 87.5k
David Judd	Member of Medical & Scientific Advisory Board	5.3yrs	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

64.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van PMCB wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.8 jaar), wat duidt op een nieuw bestuur.

PharmaCyte Biotech Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

PharmaCyte Biotech, Inc., Annual General Meeting, Apr 29, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

PharmaCyte Biotech, Inc. Announces Resignation of Jack E. Stover as Director

PharmaCyte Biotech, Inc. Announces Resignation of Gerald W. Crabtree as Chief Scientific Officer

PharmaCyte Biotech, Inc., Annual General Meeting, Dec 28, 2022

Recent updates

PharmaCyte Biotech, Inc. announced delayed 10-Q filing

PharmaCyte Biotech, Inc. announced delayed annual 10-K filing

PharmaCyte Biotech, Inc., Annual General Meeting, Apr 29, 2024

PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business

High number of new and inexperienced directors

PharmaCyte Biotech, Inc. Provides Corporate Update on Cell-In-A-Box Technology

PharmaCyte Biotech, Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

PharmaCyte Biotech, Inc. (NasdaqCM:PMCB) announces an Equity Buyback for 7,750,000 shares, for $25.19 million.

PharmaCyte Biotech, Inc. (NasdaqCM:PMCB) announces an Equity Buyback for $10 million worth of its shares.

PharmaCyte Biotech, Inc. Announces Resignation of Jack E. Stover as Director

PharmaCyte Biotech, Inc. Announces Resignation of Gerald W. Crabtree as Chief Scientific Officer

PharmaCyte Biotech, Inc., Annual General Meeting, Dec 28, 2022

PharmaCyte Biotech, Inc. Announces Management Changes

PharmaCyte Biotech says CEO to step down, announces strategic review of business

PharmaCyte Biotech, Inc. Announces Board Appointments

PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors

Iroquois Capital Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech

PharmaCyte Biotech, Inc. Commences First Phase of Two-Phase Pig Study

PharmaCyte Biotech, Inc. Reports Positive Interim Results in Malignant Ascites Mouse Model Study

Iroquois Capital Commences Consent Solicitation to Reconstitute Pharmacyte Biotech Board of Directors

Iroquois Capital Issues a Statement in Response to Pharmacyte Biotech

Iroquois Capital Delivers Open Letter to Pharmacyte Biotech Board of Directors

PharmaCyte Biotech, Inc., Annual General Meeting, Aug 25, 2022

PharmaCyte Biotech, Inc. (NasdaqCM:PMCB) announces an Equity Buyback for $10 million worth of its shares.

PharmaCyte Biotech, Inc. Initiates Studies to Confirm its Pancreatic Cancer Therapy Can Treat Malignant Ascites

Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors

PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements

PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

PharmaCyte Biotech, Inc. Appoints Matthias Löhr to the Board

PharmaCyte Biotech Receives A Notification Letter from Regulation Department of the Nasdaq Stock Market

PharmaCyte Biotech, Inc. Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

PharmaCyte Biotech, Inc Updates Status of Investigational New Drug Application to FDA

Is This A Good Time To Invest In PharmaCyte?

Pharmacyte Biotech, Inc. Study Proves Capsule Material Is Not Toxic for Encapsulated Cells

PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay

PharmaCyte Biotech, Inc. Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study

PharmaCyte Biotech, Inc. Announces Encapsulation Material Does Not Alter Cellular DNA

Pharmacyte Biotech, Inc. Releases More Positive Results from U.S. Food and Drug Administration-Required Biocompatibility Tests

Pharmacyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise

PharmaCyte Biotech: Buy The 'Dump'

PharmaCyte Biotech Common Stock Deleted from Other OTC

PharmaCyte Biotech Provides Update to Nasdaq Listing Efforts and Presents Scientific Publications Supporting Pancreatic Cancer Treatment

PharmaCyte Biotech, Inc. Announces Update on Study Progress

PharmaCyte Biotech, Inc. Announces Stability Test Results on Cells from Master Cell Bank

PharmaCyte Biotech Provides Update on Status of Activities to Lift Clinical Hold

PharmaCyte Biotech Begins DNA Sequence and Stability Studies in Response to FDA Requests for Its Clinical Trial Product

PharmaCyte Biotech Begins Physical Testing of CypCaps in Response to FDA Recommendations for Its Clinical Trial Product

PharmaCyte Biotech, Inc. Successfully Completes 9-Month Stability Study

PharmaCyte Biotech, Inc. Receives U.S. FDA Clinical Hold Letter

PharmaCyte Biotech, Inc. Announces Dr. Gerald W. Crabtree Will No Longer Serve as Chief Operating Officer But Instead Will Serve as Chief Scientific Officer

U.S. FDA Places PharmaCyte Biotech, Inc.’s Investigational New Drug Application on Hold

PharmaCyte Biotech Continues to Engage the FDA During 30-Day Comment Period

PharmaCyte Biotech, Inc. Successfully Completes Six-Month Stability Study

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd